Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (IBIO) is a biotechnology innovator providing end-to-end CDMO services and AI-driven solutions for biotherapeutics development. This page serves as the definitive source for all official company announcements, regulatory filings, and operational updates.
Investors and industry observers will find timely access to earnings reports, strategic partnerships, regulatory milestones, and technology advancements related to iBio's vaccine development and precision antibody platforms. Our curated feed ensures transparent tracking of the company's progress in accelerating biopharmaceutical production from discovery to commercialization.
All content is sourced directly from iBio's corporate communications, maintaining factual accuracy and compliance with financial disclosure standards. Bookmark this page for efficient monitoring of IBIO's developments in artificial intelligence applications for drug discovery, manufacturing expansions, and clinical trial updates.
iBio, Inc. (NYSEA: IBIO) has completed its public offering of 3,365,385 shares, along with Series A and Series B warrants, at a price of $1.04 each. The offering, partially exercised by underwriters, raised approximately $3.5 million in gross proceeds. Funds will primarily support operating costs, R&D, and general corporate needs. The Company aims to enhance its capabilities in developing new antibody treatments targeting challenging cancers and diseases. The offering was conducted under an SEC shelf registration statement effective since December 2020.
iBio, Inc. (NYSEA: IBIO) announced the pricing of an underwritten public offering of 3,365,385 shares at $1.04 each, with Series A and B warrants included. The offering aims to raise approximately $3.5 million for operating costs, particularly for research, development, and general corporate expenses, including employee payments. The closing is anticipated on or about December 9, 2022. Additionally, the underwriter has a 30-day option to purchase extra shares and warrants. This follows the company's effective shelf registration statement filed with the SEC.
iBio announced plans to conduct an underwritten public offering of common stock and Series A and B warrants, with a potential 30-day underwriter option for additional shares. The proceeds are aimed primarily at operating costs, including research and development and general corporate purposes. The offering, which is subject to market conditions, is associated with a shelf registration statement previously filed. H.C. Wainwright & Co. leads the offering management. iBio aims to strengthen its financial position while focusing on antibody development.
iBio, Inc. (NYSE: IBIO) announced that its Chief Scientific Officer, Martin Brenner, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 7, 2022, at 1:20 p.m. Eastern Time. The event will be broadcast live and archived on the company's website under the 'News & Events' section. iBio specializes in developing next-generation biopharmaceuticals utilizing computational biology to enhance antibody therapies for difficult-to-treat cancers and diseases.
iBio, Inc. (NYSE: IBIO) announced its participation in the Antibody Engineering & Therapeutics Conference 2022 in San Diego, presenting two posters highlighting applications of its AI-driven RubrYc Discovery Engine.
The presentations include AI-Designed Structural Immunogens targeting PD-1 Agonist and EGFRvIII tumor-specific epitopes. Additionally, they will showcase identification efforts of a potent PD-1 Agonist antibody and a targeted approach for tumor cells. The RubrYc Discovery Engine aims to develop effective immunotherapies for challenging cancers.
iBio, Inc. (NYSEA:IBIO) announces the immediate resignation of CEO Thomas F. Isett from both the Board of Directors and his executive duties. The current Chair, William (Chip) Clark, will oversee the leadership team during the search for a new CEO. Isett's contributions included enhancing iBio's portfolio and acquiring RubrYc’s drug discovery engine. The company emphasizes its commitment to developing innovative antibody treatments and maintaining its operations amidst leadership changes.
iBio, Inc. (NYSEA:IBIO) is divesting its contract development and manufacturing organization (CDMO) to focus on immuno-oncology assets and AI-driven drug discovery. This restructuring is expected to yield approximately 50% in annualized cost savings, reducing monthly expenses by $2.5-3.0 million. The divestiture process is aimed at advancing lead candidates like IBIO-101 and optimizing their proprietary technology, with expectations to complete the sale in 2023, contributing to a cash runway into mid-2024.
iBio has provided its preliminary unaudited financial results for the fiscal year ending June 30, 2022, reporting revenues of approximately $2.4 million, a slight increase of 1% from fiscal 2021. The company recorded a net loss of $50.3 million, expanding by $27.1 million due to rising R&D and administrative expenses. In a strategic move, iBio acquired assets from RubrYc Therapeutics, enhancing its immunotherapy portfolio. However, it has opted not to proceed with the IND submission for its COVID-19 vaccine candidate IBIO-202.
iBio announced the acquisition of RubrYc Therapeutics to enhance its immuno-oncology pipeline and AI-driven drug discovery capabilities. The acquisition includes a patented AI Drug Discovery Platform and rights to two previously licensed drug candidates, with an upfront payment of $1 million in stock. Potential development milestones of up to $5 million are also available. iBio aims to extend its cash runway and will discuss its strategic transformation and FY2022 results in a conference call on September 27, 2022.
iBio, Inc. announced successful completion of its first batch of a proprietary nucleocapsid antigen for the vaccine candidate IBIO-202 under cGMP conditions. This new vaccine aims to provide long-lasting protection against COVID-19 variants through the nucleocapsid protein, rather than the spike protein used in current vaccines. The company is analyzing data from its challenge studies to further validate this approach. iBio is actively pursuing funding opportunities with Congress to support next-generation COVID-19 vaccine development.
FAQ
What is the current stock price of Ibio (IBIO)?
What is the market cap of Ibio (IBIO)?
